JPWO2021235508A1 - - Google Patents
Info
- Publication number
- JPWO2021235508A1 JPWO2021235508A1 JP2022524526A JP2022524526A JPWO2021235508A1 JP WO2021235508 A1 JPWO2021235508 A1 JP WO2021235508A1 JP 2022524526 A JP2022524526 A JP 2022524526A JP 2022524526 A JP2022524526 A JP 2022524526A JP WO2021235508 A1 JPWO2021235508 A1 JP WO2021235508A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020089196 | 2020-05-21 | ||
| JP2020089196 | 2020-05-21 | ||
| JP2020134338 | 2020-08-07 | ||
| JP2020134338 | 2020-08-07 | ||
| PCT/JP2021/019088 WO2021235508A1 (ja) | 2020-05-21 | 2021-05-20 | 脂肪性肝疾患の治療用医薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPWO2021235508A1 true JPWO2021235508A1 (https=) | 2021-11-25 |
| JPWO2021235508A5 JPWO2021235508A5 (https=) | 2024-05-27 |
| JP7820294B2 JP7820294B2 (ja) | 2026-02-25 |
Family
ID=78707930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022524526A Active JP7820294B2 (ja) | 2020-05-21 | 2021-05-20 | 脂肪性肝疾患の治療用医薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12521375B2 (https=) |
| EP (1) | EP4154880A4 (https=) |
| JP (1) | JP7820294B2 (https=) |
| KR (1) | KR20230013126A (https=) |
| CN (1) | CN115666558A (https=) |
| AU (1) | AU2021275292A1 (https=) |
| CA (1) | CA3182134A1 (https=) |
| MX (1) | MX2022014553A (https=) |
| TW (1) | TW202207919A (https=) |
| WO (1) | WO2021235508A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4434520A4 (en) | 2021-11-19 | 2025-10-29 | Shionogi & Co | PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523225A (ja) * | 2000-12-26 | 2004-08-05 | リサーチ ディベロップメント ファンデーション | 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２ |
| JP2013542218A (ja) * | 2010-10-29 | 2013-11-21 | ファイザー・インク | Ｎ１／Ｎ２−ラクタムアセチル−ＣｏＡカルボキシラーゼ阻害剤 |
| WO2016159082A1 (ja) * | 2015-03-30 | 2016-10-06 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| JP2018501276A (ja) * | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| WO2019006324A1 (en) * | 2017-06-30 | 2019-01-03 | Quixgen, Inc. | NEW SPIROLACTONE COMPOUNDS |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548738B2 (en) | 2000-12-26 | 2003-04-15 | Research Development Foundation | ACC2-knockout mice and uses thereof |
| US20110009443A1 (en) * | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| WO2011058474A1 (en) | 2009-11-10 | 2011-05-19 | Pfizer Inc. | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| LT2776038T (lt) | 2011-11-11 | 2018-04-25 | Gilead Apollo, Llc | Acc inhibitoriai ir jų panaudojimas |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| JP6205152B2 (ja) | 2013-03-25 | 2017-09-27 | サイプレス セミコンダクター コーポレーション | シリアル通信システム、受信装置およびシリアル通信方法 |
| EP3670496A3 (en) | 2013-10-17 | 2020-09-30 | Shionogi&Co., Ltd. | Acc2 inhibitors |
| EA201892201A1 (ru) * | 2016-03-30 | 2019-03-29 | Женфит | Неинвазивная диагностика неалкогольного стеатогепатита |
-
2021
- 2021-05-20 US US17/926,273 patent/US12521375B2/en active Active
- 2021-05-20 AU AU2021275292A patent/AU2021275292A1/en not_active Abandoned
- 2021-05-20 CA CA3182134A patent/CA3182134A1/en active Pending
- 2021-05-20 KR KR1020227044828A patent/KR20230013126A/ko not_active Withdrawn
- 2021-05-20 WO PCT/JP2021/019088 patent/WO2021235508A1/ja not_active Ceased
- 2021-05-20 JP JP2022524526A patent/JP7820294B2/ja active Active
- 2021-05-20 MX MX2022014553A patent/MX2022014553A/es unknown
- 2021-05-20 EP EP21808650.2A patent/EP4154880A4/en active Pending
- 2021-05-20 CN CN202180035760.4A patent/CN115666558A/zh active Pending
- 2021-05-21 TW TW110118449A patent/TW202207919A/zh unknown
-
2025
- 2025-12-09 US US19/413,251 patent/US20260091022A1/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004523225A (ja) * | 2000-12-26 | 2004-08-05 | リサーチ ディベロップメント ファンデーション | 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２ |
| JP2013542218A (ja) * | 2010-10-29 | 2013-11-21 | ファイザー・インク | Ｎ１／Ｎ２−ラクタムアセチル−ＣｏＡカルボキシラーゼ阻害剤 |
| JP2018501276A (ja) * | 2015-01-09 | 2018-01-18 | ギリアド アポロ， エルエルシー | 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法 |
| WO2016159082A1 (ja) * | 2015-03-30 | 2016-10-06 | 塩野義製薬株式会社 | ９員縮合環誘導体 |
| WO2019006324A1 (en) * | 2017-06-30 | 2019-01-03 | Quixgen, Inc. | NEW SPIROLACTONE COMPOUNDS |
Also Published As
| Publication number | Publication date |
|---|---|
| US20260091022A1 (en) | 2026-04-02 |
| JP7820294B2 (ja) | 2026-02-25 |
| KR20230013126A (ko) | 2023-01-26 |
| CA3182134A1 (en) | 2021-11-25 |
| US12521375B2 (en) | 2026-01-13 |
| CN115666558A (zh) | 2023-01-31 |
| TW202207919A (zh) | 2022-03-01 |
| AU2021275292A1 (en) | 2022-12-15 |
| EP4154880A1 (en) | 2023-03-29 |
| EP4154880A4 (en) | 2024-06-05 |
| MX2022014553A (es) | 2022-12-15 |
| WO2021235508A1 (ja) | 2021-11-25 |
| US20230210822A1 (en) | 2023-07-06 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20231019 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20240122 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240517 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250610 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20250725 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251007 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260120 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260212 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7820294 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |